Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5′-diphosphate (ADP) in human platelets
- 1 July 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 127 (6) , 1359-1366
- https://doi.org/10.1038/sj.bjp.0702690
Abstract
Adenosine 5'-diphosphate (ADP) induces human blood platelets to aggregate and change shape, and it has been suggested that these two responses are mediated by more than one subtype of ADP receptor. The structure-activity relationships for several analogues of adenine nucleotides in causing aggregation and shape change were measured and compared in washed platelets using an aggregometer. ADP and its analogues 2-methylthioadenosine 5'-diphosphate (2-methylthio-ADP), adenosine 5'(alpha,beta-methylene)diphosphonate (AMPCP), S(P)-adenosine 5'-O-(1-thiodiphosphate) (AD-P alphaS) and adenosine 5'-O-(2-thiodiphosphate) (ADPbetaS) were used as agonists. Adenosine 5'-triphosphate (ATP) and its analogues, P1, P5-diadenosine pentaphosphate (ApsA), adenosine (5'-(alpha,beta-methylene)triphosphonate (AMPCPP), 2-methylthioadenosine 5'-triphosphate (2-methylthio-ATP) and uridine 5'-triphosphate (UTP), as well as the trypanocidal drug suramin, were used as antagonists. In general, the structure-activity relationships for both responses were similar, but for some analogues differences were observed. ADPalphaS and ADPbetaS were much more potent agonists relative to ADP for shape change than for aggregation and indeed ADPalphaS antagonized ADP-induced aggregation with an apparent pK(B) value of 5.5+/-0.1. 2-Methylthio-ATP also had different effects in aggregation and shape change, being a much higher affinity antagonist of aggregation than of shape change with an apparent pK(B) value of 7.0+/-0.2 for aggregation and 5.2+/-0.2 for shape change. These results support the suggestion that these two responses are mediated by multiple ADP receptors on human platelets, and are consistent with shape change being mediated via one receptor (the P2Y1 receptor) with aggregation requiring the activation of two receptors (the P2Y1 and another P2Y receptor).Keywords
This publication has 35 references indexed in Scilit:
- ADP can induce aggregation of human platelets via both P2Y1 and P2T receptorsBritish Journal of Pharmacology, 2000
- Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptorsEuropean Journal of Pharmacology, 1998
- P2Y1‐receptors in human platelets which are pharmacologically distinct from P2YADP‐receptorsBritish Journal of Pharmacology, 1998
- The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cellsPublished by Wiley ,1997
- Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole bloodBlood Coagulation & Fibrinolysis, 1996
- Purinergic receptors on blood plateletsPlatelets, 1996
- A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosisTrends in Pharmacological Sciences, 1995
- Effects of extracellular divalent cations on responses of human blood platelets to adenosine 5′-diphosphateBiochemical Pharmacology, 1994
- Receptors for ADP on human blood plateletsTrends in Pharmacological Sciences, 1994
- Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5′-diphosphate in human plateletsBiochemical Pharmacology, 1994